OBJECTIVES: To compare the clinical effectiveness of eprosartan and irbesartan, losartan, telmisartan and valsartan in patients with hypertension. METHODS: The clinical effectiveness analysis in accordance with the Cochrane Collaboration guidelines were performed. Only head-to head study with randomization were include to analysis. RESULTS: Eprosartan vs losartan- One RCT (head-to-head) was identify. There was no statistically significant difference between groups in change in systolic and diastolic pressure. Also there was no statistically significantly more patients achieved clinical response after 4 weeks follow-up. The incidence of adverse events were similar in both group. Eprosartan vs telmisartan- Analysis based on direct evidence (one RCT) showed statistically important difference in change diastolic pressure after 12 month, favors telmisartan: RD: 4 mmHG (95% CI: 3.51; 4.49). There was no statistically differences between compared groups in change in systolic pressure. Frequency of adverse events was also comparable between groups. Eprosartan vs valsartan or irbesartan: Because of lack of relevant study (head to head), analysis could not be performed. CONCLUSION: Analysis suggests that eprosartan has comparable efficacy to losartan. Telmisatran is more effective, compared with eprosartan, for treatment of patients with hypertension. Safety of interventions are similar.